Position in BCAB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$43,521,077
-$93,796,075 QoQ
Shares Held
5,406,345
+11.8% QoQ
Ownership
326.3%
of shares outstanding
% of Portfolio
11.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ACORN CAPITAL ADVISORS, LLC holds $393,383,952 across 21 Biotechnology names. BCAB ranks #3 (11.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
1,746,264 | $92,063,038 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,130,501 | $76,512,307 | |
| 3 | BCAB |
BioAtla, Inc.
This page
|
5,406,345 | $43,521,077 | |
| 4 | URGN |
UroGen Pharma Ltd.
|
1,673,420 | $30,088,091 | |
| 5 | PBYI |
Puma Biotechnology, Inc.
|
4,131,299 | $26,399,000 | |
| 6 | TRVI |
Trevi Therapeutics, Inc.
|
2,144,844 | $25,587,988 | |
| 7 | CADL |
Candel Therapeutics, Inc.
|
3,497,948 | $17,139,945 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
643,382 | $12,796,867 |
All Filings in BCAB
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $43,521,077 | 5,406,345 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $137,317,152 | 4,835,111 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $166,327,818 | 4,835,111 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $95,735,197 | 4,835,111 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $69,955,998 | 4,032,046 | Shares | Sole | 2025-05-19 | |
| 2024-12-31 | $119,146,959 | 4,032,046 | Shares | Sole | 2025-05-19 | |
| No filing history on record for this holder in this stock. | ||||||